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We report the case of a patient with B-Cell Acute Lymphoblastic Leukemia (ALL) who was
found to harbor a gene fusion involving the CCDC6 and RET genes. Although the RET
mutations have been identified before in other malignancies, and it is thought to represent
a driver mutation in these neoplasms, it has yet to be described in ALL. The identification
of known fusion genes conferring activating tyrosine kinase activity in neoplasms can
suggest potential therapeutic role of tyrosine kinase inhibitors (TKI), an approach that
has been exploited in several other fusion genes.
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INTRODUCTION
Sincethe discovery of a recurrent translocation in patients with chronic myeloid leukemia,
t(9:22)(q34;q11), later identified as the BCR-ABL fusion gene, the role of gene fusions involving
tyrosine kinases have been recognized as important oncogenic drivers.In ALL, the t(9:22)
translocation is the most frequent cytogenetic abnormality. BCR-ABL+ ALL patients comprise
a distinct clinical subgroup (referred as Ph+ ALL), with a more severe clinical presentation,
historically poorer prognosis, and more prevalent in adults than children (1). Therapeutic targeting
of the BCR-ABL fusion gene with TKI has improved treatment response and overall survival
for patients with Ph+ ALL. We describe here the case of a 55 year-old female who presented
with pancytopenia, lymphadenopathy, and was found to have ALL with a CCDC6-RET fusion.
Understanding the role of the different genomic alterations present in ALL is of crucial importance,
as they have prognostic implications and are evolving therapeutic targets. The first targeted therapy
in ALL was against the BCR-ABL fusion protein, which improved overall response and survival
in “fit” patients, but also allowed a promising alternative treatment strategy for elderly or frail
patients (2, 3). More recently, a subgroup of patients were noticed to share the same gene expression
profile as Ph-positive, but lack the BCR-ABL translocation. These patients have several different
genomic alterations, and are possibly targeted using different TKI’s (4). RET gene fusions and point
mutations are known driver mutation in several neoplasms, including papillary thyroid cancer
(PTC), non-small cell lung cancer (NSCLC), acute myeloid leukemia, and sporadic medullary
thyroid cancer. RET gene fusions are the main oncogenic driver in patients withmultiple endocrine
type 2 (5). RET gene fusions have not previously been described in patients with ALL (6, 7).
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FIGURE 1 | Schematic representation of the CCDC6-RET fusion gene
identified in patients with papilary thyroid cancer (8) (used with permission,
copyright Nucleic Acids Research, Oxford University Press).
CASE REPORT
A 55 year-old female patient with past medical history of type
2 diabetes, hypothyroidism and opioid dependence presented to
the ED with 2 weeks of right flank pain radiating to her right
groin. Her initial vital signs were stable, and she was afebrile.
Her physical exam was remarkable for bruising in her lower
extremities and a hemorrhagic bulla under her tongue. Palpation
of her back revealed right costovertebral angle tenderness.
Lymph node exam demonstrated a few bilateral shotty inguinal
lymph nodes.
The patient’s initial blood work was remarkable for
pancytopenia (white blood cell count 2.1 × 106/uL, Hb 112
g/L, platelets 0.03 × 109/uL), with normal renal function and
elevated Alkaline Phosphatase, AST and ALT (265, 481, and 39
U/L, respectively). Lactate dehydrogenase (LDH) was severely
elevated 17,216 U/L, with normal coagulation time, fibrinogen
and uric acid. A bone marrow flow cytometry revealed a
population of blasts that represented 77% of the sample. The
blast were positive for CD9, CD19, CD10 (variable), CD20,
cCD22, CD34, CD45, cCD79a, HLA-DR, and cTdT. The blasts
were negative for: CD2, cCD3, CD4, CD5, CD7, CD8, CD1a,
CD11b, CD11c, CD13, CD14, CD25, CD33, CD56, CD64,
CD91, CD117, CD123, CD163, cIgM, cMPO, Kappa, and
Lambda. These findings were compatible with B-lymphoblastic
leukemia. BCR/ABL was negative by PCR, and cytogenetics were
abnormal with 71,74,XXXX,XXX,XX,-3,+4,+5,+6,+6,+6,-7,
-7,+8,-9,-9,+10,-10,+11,-12,-12,-13,-14,-14,+15,+15,-16,-16,
-17,-18,-18,+19,+20,+20,-20,+21,+22,+22,+22,del(22)(q11.2),
x2[cp15]/46,XX [5].
Patient completed induction chemotherapy with R-
HyperCVAD, with complete remission as determined by
bone marrow biopsy at the end of the first cycle. Course
was complicated by neutropenic fever after the first cycle.
FoundatioOne R©Heme was sent as part of her diagnostic work
up and revealed the following genomic alterations: CCDC6-
RET gene fusion, FLT3 D835H and D835V, CDKN2A/B
loss, DNMT3A truncation in intron 14, KMT2C S793∗
(encoding MLL3) and TP53 K132R. The patient finished
induction with negative minimal residual disease (MRD) by
flow cytometry and resolution of cytogenetic abnormalities
observed at diagnosis, and underwent myeloablative
allogenic bone marrow transplant from peripheral blood
donor, with cyclophosphamide and total body irradiation
conditioning regimen.
Her initial post-transplant course was uncomplicated initially;
however, the patient developed acute graft vs. host disease
involving the skin, with a good response to steroids. Ruxolitinib
was introduced later as steroid sparing agent. To date, 500 days
since transplant, she continues to be in remission, with no MRD
in last assessment 1 year post-transplant. Patient authorized and
consented use of her information and publication of the case.
DISCUSSION
The detection of new potential driver mutations in different
neoplasms has been boosted by the introduction of several
comprehensive genomic profiling assays available for commercial
use. These assays both identify known driver mutations as well as
novel genomic alterations.
Activating mutations involving tyrosine kinase receptors
and other molecules involved in intracellular signal
amplifications/transduction are known to be important drivers
of oncogenesis. Moreover, the presence of the same mutation
across different neoplasm, often represents an important
pharmacological target. CCDC6-RET and other common
fusion partners leads to homodimerization through coiled-coil
interactions in the fusion partner protein, preserving the tyrosine
kinase activity in the RET intracellular domain and causing
ligand independent activation (9). RET autophosphorylation
lead to activation of several intracellular transduction cascades
involved in cellular proliferation, including MAPK, AKT, PKC,
JAK-STAT, PKA and PI3K (5).
RET gene fusions were first identified in patients with
PTC, followed by a subset of patients with NSCLC (10). This
mutation has been targeted recently with TKIs, offering a new
line of treatment for these patients (Figure 1) (11). CCDC6-
RET translocations are the most common type of RET fusion
present in PTC (12). These mutations are considered to have
a considerable role in oncogenesis as they are usually mutually
exclusive with other alterations such as BRAF and RAS in PTC
(13), a hypothesis that is supported by clinical response to TKIs
(5). More recently, RET gene fusions, including CCDC6 have
been identified in NSCLC (10), resulting in clinical trials for TKIs
in this subgroup (11, 14).
Several multi-kinase inhibitors with RET inhibition
are available and have been approved for several different
indications. Vandetanib (14), Lenvatinib (15), Alectinib (16),
and Cabozatinib (11) have been used in trials of NSCLC with
rearranged RET. Ponatinib (9), Sunitinib (7), Sorafenib (17),
and Axitinib (5) are molecules that inhibit multiple tyrosine
kinase proteins, but also exhibit multitarget RET inhibition, and
have been used in different clinical settings. Newer RET specific
molecules (BLU-667, LOXO-292) are currently being developed
and evaluated in different clinical scenarios (5).
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Despite the evidence for the central role of RET as a driver
mutation, different agents inhibiting RET in NSCLC and PTC
have showed different degrees of overall response rate, ranging
from 0 to 50% (5). Several hypotheses for this heterogeneous
effect exist, including significant differences in potency (as
reflected by IC50), different types of interaction with the ATP-
binding pocket of RET, and differences in non-RET tyrosine
kinase inhibition. The latter mechanism is especially of interest
given the preclinical evidence of resistance to RET inhibition
through EGFR-pathway activation in NSCLC, suggesting a
potential rational for multiple tyrosine kinase inhibition (18).
Additionally, the RET fusion partner gene might impact the
expression of RET despite not involving the tyrosine kinase
domain. Reports of different degrees of RET expression varies,
with a higher degree of RET expression in KIF5B-RET when
compared to CCDC6-RET. Additionally, KIF5B-RET has been
associated with multikinase activation independent of the RET-
tyrosine kinase (19). Evidence of heterogeneous clinical activity
of Vandetanib across different RET fusion partners has been
observed in clinically in phase 2 trials in NSCLC (14, 20).
The previously described additional mechanism in RET
mutations might explain the significant gap observed in patients
with actionable NSCLC such as EGFR, ALK, ROS1, and RET,
where the response rate and progression free survival is roughly
half for RET inhibitors (5).
As described in NSCLC, dependence on other pathways could
also potentially lead to resistance of RET inhibition. In this case,
other associated mutations such as FLT3, DNMT3A, MLL, and
TP53 act as oncogenes or tumor suppressor genes could further
contribute to resistance, as they involve other tyrosine kinase
proteins (FLT3), important epigenetic (DNTM3A, MLL3) and
DNA damage-response elements (TP53). Off note, FLT3 D835
mutations have been described before in pediatric ALL (21),
and is one of the most frequent mutations in acute myeloid
leukemia (AML). FLT3 is a well-recognized target in AML and
TKIs such as midostaurin and gilteritinib are approved to target
this mutation (22). DNMT3A mutations have been described
in 5% of 57 patient with ALL, predominantly of T-cell origin,
and are thought to lead to worse outcomes, although there is no
information in large cohorts (23). Although these mutations are
known to be present in ALL, the interactions with CCDC6-RET
is unknown and their overall prognostic implication
is unclear.
CONCLUSION
This is the first report of CCDC6-RET rearrangement in ALL
to date. The increased use of genome wide comprehensive
assays is an important tool to discover novel genomic alterations
and genomic alterations common in certain malignancies
in unexpected contexts. These findings may be suitable for
targeted therapies. The isolation of CCDC6-RET fusion raise
the possibility of directed RET inhibition with selective or
multitarget TKI in this disease. Drugs such as ponatinib
and sorafenib are already used for patients with underlying
hematologic malignancies, with a well-studied safety profile;
particularly ponatinib in Ph+ ALL. Fortunately, our patient
continues to be in remission post-transplant, but this could
be a treatment option in the future should she relapse.
Comprehensive genomic profiling including interrogation
of RET rearrangement and point mutations should be
conducted in ALL to identify the prevalence and clinical
implications of this new finding. Further characterization of
RET activation and resistance mechanism are required to assess
for better strategies to improve clinical outcomes in this subset
of malignancies.
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